Alnylam Pharmaceuticals Stock In The News
| ALNY Stock | USD 143.80 2.27 1.55% |
The overall news coverage of Alnylam Pharmaceuticals from major news outlets shows bullish sentiment on 9 news articles, blog posts, and TV commentaries analyzed in the last few months. Our overall analysis of Alnylam Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Alnylam Pharmaceuticals. The specific impact of Alnylam Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Alnylam Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Alnylam Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Alnylam Pharmaceuticals Backtesting and Alnylam Pharmaceuticals Hype Analysis. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.
Alnylam |
Alnylam Pharmaceuticals Today Top News and Investor Outlook
Alnylam Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Alnylam and other traded companies coverage. We help investors stay connected with Alnylam headlines for the 25th of April to make an informed investment decision based on correlating the impacts of news items on Alnylam Stock performance. Please note that trading solely based on the Alnylam Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.Alnylam Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Alnylam earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Alnylam Pharmaceuticals that are available to investors today. That information is available publicly through Alnylam media outlets and privately through word of mouth or via Alnylam internal channels. However, regardless of the origin, that massive amount of Alnylam data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Alnylam Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Alnylam Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Alnylam Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Alnylam Pharmaceuticals alpha.
Alnylam Largest EPS Surprises
Earnings surprises can significantly impact Alnylam Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2006-07-26 | 2006-06-30 | -0.28 | -0.31 | -0.03 | 10 | ||
2011-11-01 | 2011-09-30 | -0.35 | -0.31 | 0.04 | 11 | ||
2009-05-07 | 2009-03-31 | -0.23 | -0.19 | 0.04 | 17 | ||
2007-02-07 | 2006-12-31 | -0.3 | -0.26 | 0.04 | 13 | ||
2010-08-04 | 2010-06-30 | -0.3 | -0.35 | -0.05 | 16 | ||
2014-02-13 | 2013-12-31 | -0.45 | -0.51 | -0.06 | 13 |
Alnylam Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Alnylam Pharmaceuticals Stock. The global stock market is bearish. About 60% of major world exchanges and indexes are down. See today's market update for more information.
23rd of April 2024
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to... at finance.yahoo.com
18th of April 2024
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results at businesswire.com
15th of April 2024
Alnylam Pharmaceuticals, Inc.s Path To Profitability at simplywall.st
11th of April 2024
Alnylam Pharmaceuticals, Inc. Investigation Ongoing Contact Levi Korsinsky About Potential... at accesswire.com
10th of April 2024
Global Transthyretin Amyloidosis Treatment Market Size To Exceed USD 10.42 Billion By 2033... at finance.yahoo.com
8th of April 2024
Did Alnylam Pharmaceuticals, Inc. Mislead Investors Shareholder Rights Advocates at Levi K... at accesswire.com
5th of April 2024
Alnylam CEOs total pay nearly doubles, hitting 8.9M at bizjournals.com
20th of March 2024
Disposition of 10352 shares by Kevin Fitzgerald of Alnylam Pharmaceuticals at 190.01 subje... at benzinga.com
7th of March 2024
SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam... at benzinga.com
Alnylam Pharmaceuticals Investors Sentiment
The influence of Alnylam Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Alnylam. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Alnylam Pharmaceuticals' public news can be used to forecast risks associated with an investment in Alnylam. The trend in average sentiment can be used to explain how an investor holding Alnylam can time the market purely based on public headlines and social activities around Alnylam Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Alnylam Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Alnylam Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Alnylam Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Alnylam Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alnylam Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alnylam Pharmaceuticals' short interest history, or implied volatility extrapolated from Alnylam Pharmaceuticals options trading.
Check out Alnylam Pharmaceuticals Backtesting and Alnylam Pharmaceuticals Hype Analysis. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.52) | Revenue Per Share 14.637 | Quarterly Revenue Growth 0.312 | Return On Assets (0.05) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.